Evidence map›Paper›PMID 40369259›Full record

ReviewApplied microbiology and biotechnology2025

Substrate utilization and secondary metabolite biosynthesis in the phylum Planctomycetota.

Madeleine Kündgen, Christian Jogler, Nicolai Kallscheuer

Abstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Madeleine KündgenDepartment of Microbial Interactions, Institute for Microbiology, Friedrich Schiller University, 07743, Jena, Germany.ORCID http://orcid.org/0009-0003-2113-4411
Christian JoglerDepartment of Microbial Interactions, Institute for Microbiology, Friedrich Schiller University, 07743, Jena, Germany. christian.jogler@uni-jena.de.ORCID http://orcid.org/0000-0002-2313-3389
Nicolai KallscheuerDepartment of Microbial Interactions, Institute for Microbiology, Friedrich Schiller University, 07743, Jena, Germany. nicolai.kallscheuer@uni-jena.de.ORCID http://orcid.org/0000-0003-4925-6923

Funding

Deutsche Forschungsgemeinschaft 390713860
6 · The paper itself

Abstract

The phylum Planctomycetota is changing our understanding of bacterial metabolism, driving critical biogeochemical processes through the transformation of complex polymeric substrates into valuable bioactive compounds. Sophisticated methods for cultivation, genome sequencing and genetic strain engineering developed in the last two decades have stimulated detailed studies on cell propagation, metabolic capabilities and potential applications of phylum members beyond the mere isolation and characterization of novel taxa. This review synthesizes recent advances in understanding the Planctomycetota physiology with a focus on the degradation of phototroph-derived polysaccharides, anaerobic ammonium oxidation (anammox) and biosynthesis of secondary metabolites. New data especially collected over the last 5 years justifies more intensive research of the yet uncharacterized pathways of substrate uptake and utilization, as well as genome mining-assisted bioprospection to exploit the phylum's chemical repertoire. KEY POINTS: • Planctomycetes can degrade high-molecular-weight sugars produced by algae • Anaerobic ammonium oxidation (anammox) is used in technical applications • The first secondary metabolites were discovered in the last 5 years.

Indexed as

BacteriaSecondary MetabolismAmmonium CompoundsAnaerobiosisOxidation-ReductionPolysaccharidesAmmonium CompoundsPolysaccharidesAlgaeAquatic bacteriaBioactivityBioprospectionHigh-molecular weight sugarsPhototrophsSecondary metabolites

Identifiers

PMID40369259
PMCPMC12078418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.